Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained / How the Novo Nordisk Board Built a Weight-Loss Drug Empire
Transcript
- Lucas: So Novo Nordisk is now the most valuable company in Europe by market cap — hovering around four hundred and fifty billion dollars as of this month. And the engine of that value is two drugs: Ozempic for diabetes and Wegovy for weight loss. Luna: Which is wild when you think about it. A Danish insulin company that started in the 1920s is now bigger than LVMH, bigger than Nestlé, basically the entire luxury goods sector combined. Lucas: Yeah, it's a remarkable run. And what I wanted to dig into today is how the board made this happen. Because this wasn't a lucky bet on a hot new market — the board had to make deliberate, long-range decisions that kept the company pointed at GLP-1 science for over a decade. Luna: And if you've ever listened to this show and gotten a real practical takeaway — maybe you used a framework from one of our episodes in a meeting or just understood a complex board decision better — you know that kind of thing doesn't happen by accident. If today's episode is useful to you, the way we keep these conversations ad-free is listener support. It's buy me a coffee dot com slash fexingo. Lucas: Yeah, exactly. Coffee donations let us stay independent and avoid any sponsor influence on what we cover. So if you get value out of this, that's the link. But let's get back to Novo's boardroom. Lucas: The board's most unusual feature is its stability. The average director tenure at Novo is about fourteen years. Compare that to the typical S&P 500 board where turnover happens every six to eight years. That continuity matters when you're making bets that take fifteen years to pay off. Luna: And that stability is partly because of the foundation structure. The Novo Nordisk Foundation owns about seventy-seven percent of the voting shares. So there's no activist hedge fund rattling the cage every quarter. Lucas: Right. The foundation's sole purpose is to deploy profits into medical research and charitable causes. That means the board doesn't have to maximize quarterly earnings to please public shareholders. They can fund experiments that might not produce revenue for a decade. Luna: But there is a trade-off. With that kind of control, accountability gets murky. In 2023, the SEC opened an investigation into Novo's pricing practices — specifically how they handled Medicare pricing data. And critics said the foundation structure insulates management from real market discipline. Lucas: That's a fair point. But let's look at the specific decision that created the current value. In 2014, the board approved funding for a Phase 3 trial of semaglutide — the molecule behind both Ozempic and Wegovy. At that time, the obesity market was tiny. Most pharma companies had abandoned it after a string of safety failures. The approved drugs had terrible side effects and minimal efficacy. Luna: So the board was betting on a molecule that might not work, in a market that barely existed, while the company's core insulin business was still growing. That takes conviction. Lucas: It does. And they didn't just approve one trial. They funded a multi-year program across diabetes, obesity, and eventually cardiovascular outcomes. The SELECT trial that showed Wegovy reduces heart attack risk by twenty percent? That started in 2018, years before Wegovy was even approved for weight loss. The board committed to that timeline knowing they wouldn't have results until 2023. Luna: So the board wasn't just betting on a drug — they were betting on a new category of medicine that could reshape the entire company. And they had the structure to see it through. Lucas: Exactly. And that structure includes a board that is overwhelmingly Danish, with deep experience in pharma and basic science. The current chair, Helge Lund, is a Norwegian who ran Statoil and BG Group. But the real linchpin is Lars Rebien Sørensen, who was CEO from 2000 to 2016 and now serves on the foundation board. He was the one who pushed semaglutide forward against internal skepticism. Luna: I've read that some executives wanted to focus on insulin because it was safer. Semaglutide was a much bigger technical challenge — you have to formulate it so it survives the digestive tract and stays active for a week. The board could have said no. Lucas: They could have. And many pharma boards would have — especially given that Novo's insulin business was already printing cash. But the board had a simple policy: they invest in projects with the potential to transform standard of care. Semaglutide fit that definition, even if the commercial case was uncertain. Luna: Let's talk about the competition now. Eli Lilly's tirzepatide — sold as Mounjaro and Zepbound — is closing in fast. Some analysts think it might be more effective for weight loss. How is the Novo board responding? Lucas: The board approved a massive manufacturing expansion in 2024 — about six billion dollars to build new facilities in Denmark and France. That doubled their Wegovy output capacity. They're also funding a next-generation oral GLP-1 drug called amycretin, which could be a pill instead of an injection. Early Phase 1 data showed even better weight loss than semaglutide. Luna: So they're not just defending their turf — they're trying to leapfrog. That takes board-level willingness to allocate capital aggressively before the current product peaks. Lucas: Right. And that brings us back to the foundation structure. Novo Nordisk's board doesn't face the classic CEO dilemma where you're afraid to invest in a new product because it might cannibalize the current cash cow. The foundation board only cares about long-term value creation, so cannibalization is fine — actually it's encouraged. Luna: But let's not romanticize it too much. The SEC investigation is a real governance question. And there have been reports about the board being too insular — too many directors from the same small Danish network, not enough outside perspectives. Lucas: That's a valid critique. The board has nine members, and eight are Danish. Only one woman. The foundation appoints the board, so it's not exactly a democratic process. But you could argue that in this case, insularity led to deeper commitment. A more diverse board might have killed the obesity program when early data was mixed. Luna: So the question becomes: is the Novo model replicable? Can another pharma company adopt a foundation structure and get the same patient capital advantage? Lucas: Probably not easily. The foundation structure works because it was set up that way from the start — it's baked into the company's DNA. Trying to impose it later would require a massive shareholder vote and a cultural shift. But the lesson for any board is: if you want to make ten-year bets, you need to protect the team from short-term noise. Whether that's through dual-class shares, classified boards, or just a clear strategy communication, the principle is the same. Luna: I think the biggest takeaway for me is that the board didn't just say yes to semaglutide and walk away. They funded it, they protected it through internal skepticism, and they kept allocating capital to it for a decade. That's active stewardship, not passive oversight. Lucas: Exactly. And now they're facing a new challenge: the patent cliff. Semaglutide patents start expiring around 2032 in some markets. The board has maybe six years to build the next growth engine — whether that's amycretin, a combination drug, or something entirely different. How they manage that transition will define whether this is a sustained empire or a one-drug wonder. Luna: And with Eli Lilly investing heavily in manufacturing as well, the competitive landscape is only getting more intense. It's not going to get easier. Lucas: No, it's not. But if the board's track record holds, they'll be thinking about this already. They've got the structure, the patience, and — so far — the discipline to make the right calls. We'll see if that's enough for the next decade. Luna: That's all for this episode. Thanks for listening.